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COMMENTARY
One What? Why GI
Researchers Should Know
and Care About the One
Health Initiativehe One Health Initiative is an international move-Tment that began in 2006 and is supported by, among
others, the American Medical Association and the US Cen-
ters for Disease Control.1 Its goal is both laudable and
logical: to bring together animal, human, and environmental
health practitioners for collaborations that enhance health
and well being, broadly and globally. Sadly, although One
Health (and the related concept of Zoobiquity2) are widely
appreciated in the veterinary community, they are generally
unknown in the human medical community, especially
among subspecialists such as gastroenterologists.3 I ﬁrst
heard of One Health from a veterinary collaborator a year
ago, and an informal survey of colleagues in gastrointestinal
(GI) research suggested that most are similarly unaware of
One Health.
Veterinarians perform endoscopies and liver biopsies;
make use of advanced imaging (computed tomography,
magnetic resonance imaging, and positron emission tomog-
raphy scans) and laboratory tests; use chemotherapy and
cutting-edge interventional radiology approaches in pets with
luminal, pancreatic, and liver cancers; and manage many
diseases such as GI diseases and others on a long-term basis.
However, the veterinary and human medical systems largelyCelluexist in parallel, with many physicians and nonveterinary
school researchers having little appreciation for the breadth
of disease in animals or the sophistication involved inmodern
veterinary care. Gastroenterologists and GI researchers
outside of the veterinary community often are unaware of the
large number of potentially relevant naturally occurring ani-
mal models, many of which are the subject of innovative
research into pathophysiology and treatments.
Diseases of cats and dogs with direct relevance to human
medicine include inﬂammatory bowel disease (IBD),
pancreatitis, and hepatobiliary disease.4,5 Both dogs and
cats develop a variety of IBD syndromes with similarities to
human disease; in particular, cats develop a variant with
associated pancreatitis and cholangitis, and some species of
dogs (notably German Shepherds) develop a Crohn’s dis-
ease–like illness with perianal ﬁstulas.4 Cats can be affected
by both primary biliary cholangitis and primary sclerosing
cholangitis–like diseases, both of which may shed light on
the pathogenesis and treatment of the human equivalents.4
Companion animal models also may help researchers to
understand liver diseases including those associated with
copper overload, drug-induced injury, and regeneration.6
For example, congenital portosystemic shunts with associ-
ated liver atrophy are common in dogs, and published and
ongoing studies aimed at enhancing regeneration may
identify agents that could be useful in human beings.7,8
Many vaccines and other therapies originally developed
for animals have crossed over to human medicine. This is
particularly true for stem cell therapies (which have beenlar and Molecular Gastroenterology and Hepatology 2016;2:701–703
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ﬁstulizing IBD).9–11 Pet owners increasingly demand
state-of-the art care for their animals, and thus there are
increasing numbers of veterinary clinical trials that ulti-
mately may have human relevance. Cancers in pets are one
of the few large groups of diseases that have caught the
attention of the human health system (and the National
Institutes of Health). Companion animals develop GI
cancers—oral cancers are common in cats; both cats and
dogs develop hepatocellular, colorectal, and gastric cancers;
and insulinomas are common in ferrets.12–15 There is
increasing use of dogs as part of comparative oncology
efforts, particularly the National Cancer Institute Compara-
tive Oncology Program, which is designed to understand
tumor biology and test new chemotherapeutic agents and
other therapies.16
Animals other than pets are also of signiﬁcant interest
to the GI community. GI clinical practitioners are among
those on the front lines dealing with the fallout from
farming and livestock husbandry practices that lead to
food-borne illnesses. Wildlife and livestock can serve as
sentinels, key resources in the armamentarium against
zoonotic and other infectious diseases, many of which have
GI effects; similarly, animals can serve as important in-
dicators of toxic exposures and other environmental di-
sasters. Although this can have immediate relevance as far
as preventing human exposures, it also has research rele-
vance. The hedgehog inhibitor cyclopamine, for example,
was isolated from the California corn lily Veratrum cal-
ifornicum and identiﬁed in 1966 after extensive in-
vestigations into possible genetic and environmental
causes of outbreaks of cyclopia in sheep.17,18 Similarly, my
colleagues and I recently isolated a toxin likely responsible
for biliary atresia in livestock.19
Perhaps of greatest relevance to the readers of Cellular
and Molecular Gastroenterology and Hepatology is the
concept of One Health in the identiﬁcation of GI research
models. Historically and continuing today, rodents are the
primary in vivo animal models used to study GI disease.
Although the importance of rodents and particularly
genetically altered mice in GI research is dramatic, less well
appreciated is the potential utility of large animal models in
research. The Online Mendelian Inheritance in Animals
database has catalogued more than 1500 potential large
animal models of human disease, including those with
single-gene defects and those with more complex modes of
acquired and inherited disease.20 Large animals may prove
to be superior to rodents as models to study diseases that
result from external and environmental stressors, such as
those associated with obesity, diabetes, and cancer. Pigs, for
example, are particularly useful in studying liver diseases,
especially nonalcoholic fatty liver disease.21 Large animals
may better mimic human physiology than rodents and this
may, for certain experiments, outweigh the increased cost
and other problems in using large animals. Other advan-
tages of large animals include longer life spans than rodents,
larger sizes that enable more human-like therapies (and
more frequent monitoring of certain side effects), and a
greater tolerance for imaging and biopsies.This issue of Cellular and Molecular Gastroenterology and
Hepatology includes 2 contributions that highlight the
relevance of One Health concepts in GI research. Ziegler
et al22 review the use of large animals, particularly pigs, as
physiologically relevant models of luminal GI disease, noting
that pigs are in many ways superior to rodents as models to
study the intestine. Anwer’s23 Paths and Places column
provides practical advice for researchers in veterinary
schools and also points out the criticisms veterinary
researchers face when trying to obtain funding for projects
that link naturally occurring animal models (which often
cannot be manipulated genetically) to human diseases. Both
articles make clear, as this commentary also has empha-
sized, that better understanding of the power of animal
models and developing and strengthening the links between
veterinary and human medicine signiﬁcantly could beneﬁt
human (as well as animal) health. Although One Health
envisions broad solutions, often at the policy level, for the
treatment and prevention of health problems worldwide,
integrated research is an important component and one to
which all GI researchers can contribute.
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